The KHCs we have developed are new type of cells and have different characteristics from the primitive cells and pluripotent cells reported so far.
First of all, KHCS expresses a primitive endodermal marker, but unlike this, its differentiation ability differentiates into ectoderm, mesoderm, and endoderm.
It has the same differentiation ability as iPSC, but a completely different marker is expressed. In other words, the expression of protein markers that inhibit the metastasis of cancer markers, CD3, and CD81 markers, or kill cancer, is noticeable. In addition, KHCS will have a large number of down-age markers, which will not only extend the healthy lifespan of humans, but will also be a game changer that will change the paradigm of humanity.
In terms of tumorigenicity which is the most important point for cell therapy, it is very safe, that is KHCs without tumorigenicity or immunogenicity.
The test is at 15th week after transplantation of KHCs.
| Conditions | Contents |
| Mouse type | Immunodeficient mouse (SCID) |
| Transplantation site | Testis |
| Monitoring period | 15 weeks |
KHCs showed no tumor formation in SCID mice
indicating extremely low tumorigenicity and supporting their safety for cell therapy and regenerative medicine.
The absence of HLA expression in KHCs suggests low immunogenicity, supporting their safe allogeneic use and potential for mass production.
KHCs exhibit increased expression of blastocyst markers (GATA4, GATA6, SOX7, SOX17) suggesting a more primitive state and broader differentiation potential.
KHCs show upregulated expression of anti-aging genes (NAMPT, SIRT1), suggesting potential to reduce cellular damage, maintain functionality, and suppress aging.
